These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29596876)

  • 1. Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: A retrospective study evaluating long-term efficacy and safety.
    Khemis A; Kelati A; Montaudié H; Lacour JP; Passeron T
    J Am Acad Dermatol; 2018 Oct; 79(4):758-760. PubMed ID: 29596876
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study.
    Yamaguchi Y; Takatsu N; Ootaki K; Nakagawa H
    J Dermatol; 2020 Jun; 47(6):569-577. PubMed ID: 32275086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L
    Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
    Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
    J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Am Acad Dermatol; 2018 Jul; 79(1):155-157. PubMed ID: 29307635
    [No Abstract]   [Full Text] [Related]  

  • 6. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
    Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
    N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study.
    Georgakopoulos JR; Ighani A; Phung M; Yeung J
    J Am Acad Dermatol; 2018 May; 78(5):1019-1020. PubMed ID: 29180095
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
    Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
    N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases.
    Pinter A; Wilsmann-Theis D; Peitsch WK; Mössner R
    J Dermatol; 2019 May; 46(5):426-430. PubMed ID: 30786053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.
    Plachouri KM; Chourdakis V; Georgiou S
    Drugs Today (Barc); 2019 Sep; 55(9):587-593. PubMed ID: 31584575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
    Tong Y; Peranteau AJ; Nawas Z; Tyring SK
    Skin Therapy Lett; 2017 Jan; 22(1):1-6. PubMed ID: 28122092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
    Papp KA; Reich K; Paul C; Blauvelt A; Baran W; Bolduc C; Toth D; Langley RG; Cather J; Gottlieb AB; Thaçi D; Krueger JG; Russell CB; Milmont CE; Li J; Klekotka PA; Kricorian G; Nirula A
    Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience.
    Momose M; Asahina A; Umezawa Y; Nakagawa H
    J Dermatol; 2018 Mar; 45(3):318-321. PubMed ID: 29194723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of brodalumab for the treatment of psoriasis.
    Iznardo H; Puig L
    Expert Opin Drug Saf; 2020 Apr; 19(4):365-372. PubMed ID: 32053396
    [No Abstract]   [Full Text] [Related]  

  • 17. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients.
    Masson Regnault M; Konstantinou MP; Khemis A; Poulin Y; Bourcier M; Amelot F; Bulaï Livideanu C; Paul C
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1491-1496. PubMed ID: 28585707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
    Attia A; Abushouk AI; Ahmed H; Gadelkarim M; Elgebaly A; Hassan Z; Abdel-Daim MM; Negida A
    Clin Drug Investig; 2017 May; 37(5):439-451. PubMed ID: 28197901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).
    Mrowietz U; Leonardi CL; Girolomoni G; Toth D; Morita A; Balki SA; Szepietowski JC; Regnault P; Thurston H; Papavassilis C;
    J Am Acad Dermatol; 2015 Jul; 73(1):27-36.e1. PubMed ID: 25982539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.